key: cord-1046462-zt7jo0eu authors: Chen, Yu; Liu, Qianyun; Zhou, Li; Zhou, You; Yan, Huan; Lan, Ke title: Emerging SARS-CoV-2 variants: why, how, and what’s next? date: 2022-05-02 journal: Cell Insight DOI: 10.1016/j.cellin.2022.100029 sha: 5ceb12f9400438b8a4510acc97fe1dfb3da85811 doc_id: 1046462 cord_uid: zt7jo0eu The emergence of the SARS-CoV-2 Omicron variant poses a striking threat to human society. More than 30 mutations in the Spike protein of the Omicron variant severely compromised the protective immunity elicited by either vaccination or prior infection. The persistent viral evolutionary trajectory generates Omicron-associated lineages, such as BA.1 and BA.2. Moreover, the virus recombination upon Delta and Omicron co-infections has been reported lately, although the impact remains to be assessed. This minireview summarizes the characteristics, evolution and mutation control, and immune evasion mechanisms of SARS-CoV-2 variants, which will be helpful for the in-depth understanding of the SARS-CoV-2 variants and policy-making related to COVID-19 pandemic control. Since the outbreak of COVID-19 in December 2019, 504 million cumulative cases and 6.2 37 million deaths have been reported globally (https://covid19.who.int/). The etiological pathogen 38 causing the pandemic is a novel human coronavirus, named SARS-CoV-2 (also known as 2019-39 nCoV), which uses angiotensin converting enzyme 2 (ACE2) as a receptor to invade host cells 1,2 . 40 possibility of reverse mutations should be considered 63 . 132 133 Unlike the Spike mutations, mutations in the nsps, noncoding sequences, and other structural 135 proteins are not extensively studied. As mentioned above, it is more difficult for the nsps mutations 136 to be retained, and the known mutations or deletions in pp1a and pp1a/b are relatively rare. However, 137 it is still important to study these mutations or deletions, considering their importance in coronavirus' of ExoN's mismatch excision should be precisely tuned to "control" the mutation rate for better 158 The ExoN activity of the nsp10/14 complex contributes to the control of the mutation rate and 160 plays a role in the resistance against some types of antiviral nucleoside analogs. As Remdesivir 161 impairs the elongation of RNA products, it was initially expected to be a highly competent drug 162 candidate against SARS-CoV-2 70-72 . Studies in mouse hepatitis virus (MHV) also supported that the 163 GS-5734 can be a potential effective pan-CoV antiviral, and an MHV mutant lacking ExoN 164 proofreading was even more sensitive to remdesivir (GS-5734) 68,73 . However, the clinical 165 improvement rate for patients receiving remdesivir within 7 days was only 3% against SARS-CoV- The emergence of new SARS-CoV-2 variants is probably inevitable based on the following 180 facts: 1). There is a large number of SARS-CoV-2 infected populations; 2). the mutation rate of 181 SARS-CoV-2 is relatively high; 3). SARS-CoV-2 has jumped to wild animals that can serve as a 182 reservoir for virus evolution. Therefore, this COVID-19 pandemic will most likely not end with 183 Omicron. SARS-CoV-2 may finally coexist with humans as other seasonal human coronaviruses 184 (such as 229E, OC43, NL63, and HKU1, which cause common cold-like respiratory symptoms). 185 However, this coexistence should be maintained based on full completion of massive highly-186 effective vaccinations and convenient access to anti-CoV drugs rather than out of control. Mutations in coronavirus nonstructural protein 10 decrease virus 408 replication fidelity Coupling of N7-methyltransferase and 3'-5' exoribonuclease with SARS-410 CoV-2 polymerase reveals mechanisms for capping and proofreading Structural basis for inhibition of the RNA-dependent RNA polymerase from 413 SARS-CoV-2 by remdesivir Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir. 415 Innovation 2 Remdesivir is a direct-acting antiviral that inhibits RNA-dependent 417 RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is 420 Mediated by the Viral Polymerase and the Proofreading Exoribonuclease Remdesivir for the Treatment of Covid Remdesivir in adults with severe COVID-19: a randomised, double-blind, 426 placebo-controlled, multicentre trial Efficacy and safety of favipiravir, an oral RNA-dependent RNA 429 polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, 430 open-label, multicenter, phase 3 clinical trial Experimental Treatment with Favipiravir for COVID-19: An Open-Label 434 A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir 79 Safety and efficacy of Favipiravir in moderate to severe 439 SARS-CoV-2 pneumonia Omicron Variant (B.1.1.529): Infectivity, Vaccine 442 Breakthrough, and Antibody Resistance Decreased severity of disease during the first global omicron variant 445 tshwane, south africa. International journal of 446 infectious diseases : IJID : official publication of the International Society for Infectious 447 Diseases Omicron SARS-CoV-2 new variant: 449 global prevalence and biological and clinical characteristics. European review for medical 450 and pharmacological sciences Early assessment of the clinical severity of the SARS-CoV-2 omicron 452 variant in South Africa: a data linkage study Host barriers to SARS-CoV-2 demonstrated by ferrets in a high-455 exposure domestic setting Transmission of SARS-CoV-2 on mink farms between humans 458 and mink and back to humans Multiple spillovers from humans and onward transmission of SARS-461 CoV-2 in white-tailed deer Infection and Rapid Transmission of SARS-CoV-2 in Ferrets SARS-CoV-2 infection, disease and transmission in domestic cats. 466 Emerging microbes & infections 9 Infection of dogs with SARS-CoV-2 SARS-CoV-2 Infection and Hospitalization Among Adults Aged >/=18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant 472 473 MMWR. Morbidity and mortality weekly report SARS-CoV-2 Omicron virus causes attenuated disease in mice and 476 hamsters Attenuated replication and pathogenicity of SARS-CoV-2 B Immune escape by SARS-CoV-2 Omicron variant and structural basis of its 489 effective neutralization by a broad neutralizing human antibody VacW-209 Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million 492 residents of Wuhan, China Rapid development of an updated mRNA vaccine against the SARS-495 CoV-2 Omicron variant Vaccine effectiveness of two and three doses of CoronaVac against COVID-19 in Hong Kong. medRxiv Boosting with Omicron-matched or historical mRNA vaccines increases 500 neutralizing antibody responses and protection against B.1.1.529 infection in mice. 501 bioRxiv : the preprint server for biology mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits 503 comparable B cell expansion, neutralizing antibodies and protection against Omicron. 504 bioRxiv : the preprint server for biology A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent 507 and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role 510 in the Alpha variant B.1.1.7 Effects of common mutations in the SARS-CoV-2 Spike RBD and its 513 ligand, the human ACE2 receptor on binding affinity and kinetics Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific 516 neutralizing antibodies for tracking immune escape variants Epitope 519 Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV Higher infectivity of the SARS-CoV-2 new variants is associated with 528 An insight from structural data CoV 2 spike mutants Increase ACE2 recognition 531 but reduce affinity for neutralizing antibody SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from 534 neutralizing antibody responses Structural impact on SARS-CoV-2 spike protein by D614G substitution Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R 539 mutation Functional evaluation of the P681H mutation on the proteolytic activation 541 of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike. iScience 25, 103589 Structural and Functional Basis of SARS-CoV-2 Entry by Using Human 544